Share this Page:
A recent study published in the journal Science Direct suggests that lymph node dissection (lymphadenectomy) in patients with non-metastatic renal cell carcinoma (RCC) at high risk of recurrence/spread could be used to identify patients who are most likely to benefit from adjuvant therapy.
In the study, the researchers retrospectively assessed the progression of the disease in 730 patients after nephrectomy. Thirty-five percent of these patients were high-risk based on tumour stage and grade, node status, and performance status. In the patients where cancer cells where found in the lymph nodes (node-positive), there was a five to six times increased likelihood of disease progression at 12 months. These patients would, therefore, be more likely to benefit from adjuvant therapy.
